Platelet‐activating factor (PAF) is known as an important mediator of anaphylaxis and, therefore, may possibly serve as a direct target for anti‐anaphylactic drugs. We recently reported that a synthetic N‐terminally biotinylated peptide, BP21, alleviates hypothermia and vascular hyperpermeability during anaphylactic reactions in a mouse model of anaphylaxis via the direct binding of a Tyr‐Lys‐Asp‐Gly sequence in the peptide to PAF. In this study, we investigated the effect of BP21 on in vivo anaphylactic hypotension. Results showed that BP21 significantly inhibited anaphylactic hypotension in a dose‐dependent manner, with peak severity being reached within 20 minutes. Adrenaline, which is the recommended first line treatment for anaphylactic patients, did not inhibit anaphylactic hypothermia. The combined administration of BP21 with adrenaline inhibited both hypotension and hypothermia, even at both low doses, more effectively compared with solo administration of BP21 or adrenaline. These results suggested that BP21 could potentially be a novel anti‐anaphylactic agent for targeting PAF in vivo.

中文翻译：

---

生物素化的肽BP21可减轻过敏性小鼠的低血压。

血小板激活因子（PAF）被认为是过敏反应的重要介体，因此，它可能是抗过敏药的直接靶标。我们最近报道了一种合成的N端生物素化肽BP21，通过该肽中Tyr-Lys-Asp-Gly序列与PAF的直接结合，减轻了过敏反应小鼠模型的过敏反应中的体温过低和血管通透性过高。在这项研究中，我们调查了BP21对体内过敏性低血压的影响。结果表明，BP21以剂量依赖性方式显着抑制过敏性低血压，严重程度在20分钟内达到峰值。肾上腺素是过敏性患者的推荐一线治疗药物，它不能抑制过敏性体温过低。与单独给药BP21或肾上腺素相比，将BP21与肾上腺素联合给药可同时抑制低血压和体温过低，即使在低剂量时也是如此。这些结果表明，BP21可能是一种在体内靶向PAF的新型抗过敏药。